Literature DB >> 15108044

Patterns of treatment failure following radiotherapy with combination chemotherapy for patients with high-risk stage IIB cervical carcinoma.

Tchan-Kyu Park1, Ja-Young Kwon, Sang-Wun Kim, Sung-Hoon Kim, Soo-Nyung Kim, Gwi Eon Kim.   

Abstract

BACKGROUND: To evaluate the patterns of treatment failure in patients with stage IIB cervical carcinoma with high-risk factors following radiotherapy given concurrently with combination chemotherapy.
METHODS: A retrospective analysis of 349 patients with stage IIB cervical carcinoma with high-risk factors (lesion size >/= 4 cm, lymph node metastasis, high-risk cell type) treated by radiotherapy and cisplatin-based chemotherapy was performed. Sites of treatment failure were categorized as pelvic, pelvic plus distant metastases, and distant metastases alone. Pelvic failure included local and pelvic nodal failures.
RESULTS: Of the 349 patients, treatment failure occurred in 79 patients (22.6%). Forty-six (13.2%) had persistent disease and 33 (9.5%) had recurrent disease. Among these 79 patients, overall pelvic failure was observed in 67%, of whom 72% had local failure; 19%, pelvic nodal failure; and 9%, local with pelvic nodal failure. Incidences of distant metastases alone and pelvic with distant metastases were 24% and 9%. In the 26 patients with distant metastases either alone or combined with pelvic failure, the most frequent metastatic region was the paraaortic lymph node (50%). The distant metastasis rate was 6.5% (19/289) in the pelvic tumor control group and 11.6% (7/60) in the pelvic failure group. Pelvic failure was the most frequent failure in the group with tumor size of 4 cm or more, whereas, for the positive-lymph-node group, distant metastasis was most frequent and metastases to paraaortic lymph nodes were common. The incidences of pelvic failure alone and distant metastases were similar in the high-risk cell-type group, and the distant metastasis regions were mostly paraaortic lymph nodes.
CONCLUSION: Although systemic chemotherapy was administered concurrently with radiotherapy, the incidence of pelvic failure was highest, followed by paraaortic lymph node metastases, in patients with stage IIB cervical carcinoma with high-risk factors, following radiotherapy with combination chemotherapy. To evaluate the patterns of treatment failure in patients with stage IIB cervical carcinoma with high-risk factors following radiotherapy given concurrently with combination chemotherapy.

Entities:  

Mesh:

Year:  2004        PMID: 15108044     DOI: 10.1007/s10147-003-0378-9

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  6 in total

Review 1.  Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer.

Authors:  Noriaki Sakuragi
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

2.  Treatment outcomes of patients with cervical cancer with complete metabolic responses after definitive chemoradiotherapy.

Authors:  Cem Onal; Mehmet Reyhan; Ozan C Guler; Ali Fuat Yapar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

3.  Prognostic significance of positive lymph node number in early cervical cancer.

Authors:  Jung-Woo Park; Jong Woon Bae
Journal:  Mol Clin Oncol       Date:  2016-03-30

4.  Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy. In regard to Vojtíšek et al.

Authors:  Cem Onal; Guler Yavas; Cagdas Yavas
Journal:  Strahlenther Onkol       Date:  2021-08-02       Impact factor: 3.621

5.  Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer.

Authors:  Kyungmi Yang; Won Park; Seung Jae Huh; Duk-Soo Bae; Byoung-Gie Kim; Jeong-Won Lee
Journal:  Radiat Oncol J       Date:  2016-12-12

6.  Radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage IIB cervical cancer.

Authors:  Yanlan Chai; Tao Wang; Juan Wang; Yunyi Yang; Ying Gao; Jiyong Gao; Shangfeng Gao; Yueling Wang; Xi Zhou; Zi Liu
Journal:  BMC Cancer       Date:  2014-02-04       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.